MAIER PAUL V
Known title: DirectorCIK: 0001182615
Associated companies
Transaction History
| ETON | ▲ Buy | Option Exercise | 50,000 | $189K | 8/28/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 36,387 | $2.1M | 8/28/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 13,485 | $812K | 8/28/2026 | View on chart |
| ETON | ▼ Sell | Open Market | 128 | $8K | 8/28/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Eton Secures U.S. License for LIBERVANT Buccal Film
Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.
Eton Secures U.S. License for LIBERVANT Buccal Film. Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.